Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer
T Takahashi, N Yamamoto, T Nukiwa, K Mori… - Anticancer …, 2010 - ar.iiarjournals.org
The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …
[引用][C] Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer
T TAKAHASHI, N YAMAMOTO, Y SEGAWA… - Anticancer …, 2010 - pascal-francis.inist.fr
Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
[引用][C] Phase II study of erlotinib in Japanese patients with advanced non‐small cell lung cancer
T TAKAHASHI - Anticancer Res, 2010 - cir.nii.ac.jp
Phase II study of erlotinib in Japanese patients with advanced non‐small cell lung cancer |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
[PDF][PDF] Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer
T TAKAHASHI, N YAMAMOTO… - ANTICANCER …, 2010 - ar.iiarjournals.org
The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
T Takahashi, N Yamamoto, T Nukiwa, K Mori… - Anticancer …, 2010 - europepmc.org
Results Of the 46 patients, 13 were assessed to have a partial response and 9 had stable
disease. The median duration of response was 449 days and time to progression was 75 …
disease. The median duration of response was 449 days and time to progression was 75 …
[PDF][PDF] Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer
T TAKAHASHI, N YAMAMOTO, T NUKIWA… - ANTICANCER …, 2010 - Citeseer
The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer
T Takahashi, N Yamamoto, T Nukiwa… - Anticancer …, 2010 - pubmed.ncbi.nlm.nih.gov
The aim of this study was to evaluate the efficacy and safety of erlotinib, an epidermal growth
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …
factor receptor tyrosine kinase inhibitor, in Japanese patients with relapsed or recurrent …